Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation

Mona Mahrous Abdelaty¹*, Amr Gawaly¹, Gamal M. Fathy², Ibrahim Kabbash³ and Atef Taha¹

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment for adult patients with acute lymphoblastic leukemia (ALL). Cyclophosphamide plus total body irradiation (TBI/Cy) or plus busulfan (Bu/Cy) is a widely used pre-transplant conditioning regimen for ALL. We retrospectively compared the overall survival (OS), disease-free survival (DFS), and other transplant outcomes of allo-HSCT in 119 adult patients with ALL who received an HLA-matched sibling allo-HSCT using TBI-based versus non-TBI-based conditioning regimens. Patients were divided into two groups by their conditioning regimen: TBI/Cy or Bu/Cy.

Results: Median OS was 11 months in the TBI/Cy group and 6.2 months in the Bu/Cy group. Median DFS was 11.1 months in the TBI group versus 6.8 months in the Bu group, without a statistically significant difference. A higher risk of relapse was observed with the Bu/Cy regimen (HR 2.709, CI 95% 1.106 to 6.638, p = 0.029). Patients who received a transplant in ≥ CR2 were associated with poor DFS.

Conclusion: Despite the high relapse rate in the non-TBI regimen (Bu/Cy), both regimens had no statistically significant differences in OS, DFS, and NRM. Additional prospective studies are indeed warranted to evaluate the long-term outcomes of radiation-free regimens, including oral and intravenous busulfan, and compare these regimens with TBI-based ones.

Keywords: Allogeneic hematopoietic stem cell transplantation, Acute lymphoblastic leukemia, Conditioning, Total body irradiation, Busulfan

Background
ALL generally has an excellent prognosis in children with promising chemotherapy regimens [1]. In contrast, it is still challenging in adults as it is associated with poor survival outcomes and high relapse rates when treated with chemotherapy alone. Allo-HSCT is generally considered a lifesaving option that is able to consolidate remission resulting in long-term DFS is adults [2].

Combinations of cyclophosphamide with either TBI or busulfan are the most commonly used myeloablative conditioning regimens (MAC) for allo-HSCT in adult ALL [3]. TBI has dual immunosuppressive and antileukemic properties with the ability to reach the hidden sites. It has expected better survival outcomes without an increase in relapse or transplant-related mortality (TRM). Unfortunately, at higher doses, TBI is associated with a potential risk of early and late complications [4].
Although busulfan-containing regimens can produce comparable outcomes with lower TRM, the oral form has wide variability in the absorption and metabolism. Also, high relapse rates have been observed with low levels of busulfan, while many risks including veno-occlusive disease (VOD) have been related to higher levels [5].

Many studies have been carried out to evaluate the effect of different regimens on transplant outcomes, but the ideal conditioning regimen for adult ALL patients remains unknown [3]. This retrospective study aims to compare transplant outcomes in ALL patients using the TBI/Cy and oral Bu/Cy as MAC regimens.

Methods
A retrospective cohort study was done on data obtained from a tertiary center’s bone marrow transplantation unit registry. The medical files of adult patients with ALL who received a transplant during the period 2000 to 2016 were reviewed. Patients aged 19 years or above at the time of first allo-HSCT from an HLA-matched sibling donor using TBI/Cy or Bu/Cy as a MAC regimen were included, either in first complete remission (CR1), CR2, or beyond. All patients had adequate performance scale and negative serology for the hepatitis B virus and the human immune deficiency virus (HIV).

Patients aged 60 years or above and those who received syngeneic or haploidentical allo-HSCT were excluded.

Detailed history has been reviewed, including data about age, sex, time from diagnosis to transplantation, Philadelphia chromosome, and disease status at transplantation time, associated comorbidities, viral status, donor type, stem cell source, CD34 cell dose, graft versus host disease (GVHD) prophylaxis, and transfusion requirements. Allo-HSCT outcome was assessed with the following parameters: time to engraftment, acute and chronic GVHD, incidence and severity of infections, and conditioning regimen-related toxicities. Survival outcomes included OS, DFS, NRM, and relapse.

Conditioning regimens
Patients included in our study were divided into two groups based on their conditioning regimens:

Group 1 included ALL patients who received allo HSCT from 2000 to 2015 and received TBI/Cy. The TBI dose was 12 Gy fractionated over 5 days (from day −10 to day −6). Cy was administrated as 30 mg/day (from day −5 to day −2 of the stem cell infusion).

Group 2 included ALL patients who received allo HSCT from 2000 to 2016 and received Bu/Cy. The dose of oral busulfan was 16 mg/kg total dose over 4 days to be given as 4 mg/day orally. The Cy dosage over 4 days was 120 mg/kg IV to be given as 30 mg/day.

GVHD prophylaxis
All patients received prophylaxis for GVHD using methotrexate (MTX) and cyclosporine (CSA). MTX dose was 15 mg/m² IV given on day +1 then changed to 10 mg/m² on days +3, +6, and +11, as well as folinic acid rescue 15 mg/m² IV TDS for just 24 h on the day after MTX injection. MTX was monitored by the degree of mucositis and bilirubin level with the appropriate drug titration. CSA was administered in two divided doses from day −1 at a dose of 3 mg/kg/day IV that was replaced by an oral form once tolerated. The dose was modified to reach a therapeutic plasma CSA level of 200–250 mg/ml. Renal functions and electrolytes were also monitored with drug titration accordingly.

Supportive care
Gastric protection by pantoprazole, antiemetics, using ondansetron were initiated at the start of the conditioning regimens and maximized as needed. All patients were given uromitexan guard against cyclophosphamide-induced hemorrhagic cystitis. Seizure prophylaxis by phenytoin was given before and during the administration of busulfan. Local mouth care and prophylaxis against bacterial, fungal, and viral infections were also given to all patients. Pneumocystis Jirovecii infection prophylaxis was done by trimethoprim-sulfamethoxazole (stopped in day −2 and re-initiated after engraftment). Preemptive treatment for cytomegalovirus (CMV) reactivation was given according to close molecular monitoring. Supportive irradiated blood products were administrated when needed; whole blood and granulocyte colony-stimulating growth factors (G-CSF) were received in some patients until neutrophil recovery.

Study endpoints and operational definitions
The primary endpoints were OS and DFS. OS was defined as time to death or last contact for survivors. DFS was identified as a time to treatment failure (relapse or death); for survivors, it was considered as the last contact in remission. The secondary endpoints were relapse and NRM. Relapse was considered as the recurrent appearance of hematological disease. We define NRM as a death in remission.

Engraftment was identified as the first of three consecutive days with an absolute count of neutrophils > 500/μL and platelets > 20,000/μL (unsupported) [6]. The diagnosis and grading of acute and chronic GVHD were based on the established criteria [7, 8]. VOD diagnosis was based on the Baltimore clinical criteria [9]. Mucositis was identified and graded according to the National Cancer Institute (NCI-CTC) criteria [10], and grade 1 was considered as mild, grade 2 as moderate, and grades 3 and 4 as severe mucositis. Renal complications in our study were defined when serum creatinine was ≥
2mg/dl and/or requiring CSA cessation. CMV infection or reactivation was diagnosed when 2 consecutive titres of CMV DNA are above 500 copies/mL in the presence of GVHD or above 1000 copies/mL in the absence of GVHD.

Statistical analysis
The collected data were organized, tabulated, and statistically analyzed by SPSS version 24 (Statistical Package for Social Studies) created by IBM, Illinois, Chicago, USA. For numerical values, the range, mean, and standard deviations were calculated. The differences between mean values were tested using (t) test while the Mann-Whitney test (Z) was used for other variables where data were not normally distributed. For categorical variables, the number and percentage were calculated, and differences between subcategories were tested using the chi-square test. When chi-square was not appropriate, Fisher and Monte Carlo exact tests were used as appropriate.

Table 1 Baseline characteristics of the study population

| Variable                      | TBI/Cy (n = 78) | Bu/Cy (n = 41) | p value |
|-------------------------------|-----------------|----------------|---------|
| Age (years)                   | 27.64 ± 7.67    | 27.46 ± 7.00   | 0.902   |
| (19–49)                       | (19–41)         |                |         |
| Recipient sex                 |                 |                |         |
| Males                         | 56 (71.8)       | 30 (73.2)      | 0.873   |
| Females                       | 22(28.2)        | 11(26.8)       |         |
| Immunophenotype               |                 |                |         |
| B                             | 52 (66.7)       | 27 (65.9)      | 0.929   |
| T                             | 26 (33.3)       | 14 (34.1)      |         |
| Performance status            |                 |                |         |
| 0–1                           | 75 (96.2)       | 38 (92.7)      | 0.339   |
| 2                             | 3 (3.8)         | 3 (7.3)        |         |
| Ph chromosome status          |                 |                |         |
| Negative                      | 60 (76.9)       | 32 (78)        | 0.889   |
| Positive                      | 18 (23.1)       | 9 (22)         |         |
| Disease status at transplant  |                 |                |         |
| CR 1                          | 40 (51.3)       | 16 (39)        | 0.203   |
| ≥ CR 2                        | 38 (48.6)       | 25 (61)        |         |
| Pre-transplant Comorbidities  |                 |                |         |
| No                            | 76 (85.9)       | 37 (90.2)      | 0.497   |
| Yes                           | 11 (14.1)       | 3 (9.8)        |         |
| Donor sex                     |                 |                |         |
| Females                       | 33 (42.3)       | 22 (53.7)      | 0.238   |
| Males                         | 45 (57.7)       | 19 (64.3)      |         |
| Donor/recipient CMV seropositivity |           |                |         |
| Mismatched                    | 7 (9)           | 2 (4.9)        | 0.717   |
| Matched                       | 71 (91)         | 39 (95.1)      |         |
| *Diagnosis to transplant lag period (month) | 16.25 (14–137.3) | 13.5 (4.9–73.2) | 0.114 |

Values are expressed as mean (range) and n (%)

For risk estimation, odds ratio was calculated and its 95% confidence interval. For calculation of the hazard ratio and its 95% confidence interval for the independent effect of each predictor on a certain outcome to occur during the survival period of studied patients, Cox regression was performed. The level of significance was adopted at p < 0.05.

Table 2 Transplant outcomes

| Variable                          | TBI/Cy (n = 78) | Bu/Cy (n = 41) | p value |
|-----------------------------------|-----------------|----------------|---------|
| Neutrophil engraftment (days)     | 17(9–35)        | 14(10–24)      | 0.002   |
| Platelet engraftment (days)       | 15(8-47)        | 14(7–45)       | 0.017   |
| Acute GVHD                        |                 |                | 0.723   |
| Chronic GVHD                      |                 |                | 0.106   |
| Relapse after transplant          |                 |                | 0.034   |
| No                                | 69 (88.5)       | 30 (73.2)      |         |
| Yes                               | 9 (11.5)        | 11 (26.8)      |         |
| NRM                               |                 |                | 0.278   |
| No                                | 48 (61.5)       | 21 (51.2)      |         |
| Yes                               | 30 (38.5)       | 20 (48.8)      |         |

Values are expressed as median (range) and n (%)

Table 3 Multivariate analysis of non-relapse mortality, relapse, and engraftment

| Endpoints of the study | HR (95% CI) | P   |
|------------------------|-------------|-----|
| NRM                    |             |     |
| Variables              |             |     |
| Conditioning           | 0.692(0.310–1.545) | 0.369 |
| Age of recipient       | 1.019(0.975–1.065) | 0.396 |
| Disease status at BMT  | 1.639(0.775–3.469) | 0.196 |
| Ph chromosome status   | 0.808(0.329–3.995) | 0.641 |
| CD34 dose              | 1.008(0.917–1.108) | 0.873 |
| Comorbidities          | 1.380(0.512–3.721) | 0.524 |
| Diagnosis to transplant lag period | 1.005(0.989–1.023) | 0.531 |
| Relapse                |             |     |
| Variables              |             |     |
| Conditioning (TBI/Cy versus Bu/Cy) | 2.709(1.106–6.638) | 0.029 |
| Age of recipient       | 0.977(0.914–1.045) | 0.500 |
| Philadelphia chromosome status | 0.1321(0.437–3.995) | 0.622 |
| Engraftment            |             |     |
| Variables              |             |     |
| Conditioning (TBI/Cy versus Bu/Cy) | 1.229(0.809–1.868) | 0.333 |
| Disease status at BMT  | 1.085(0.774–1.521) | 0.635 |
| CD34 dose              | 0.999(0.942–1.059) | 0.970 |

HR hazard ratio, CI confidence interval
Results
A total of 119 adult patients with ALL received allo-HSCT from HLA-matched sibling donors from January 2000 to December 2016. Seventy-eight patients were transplanted using TBI/Cy, and forty-one patients were transplanted using oral Bu/Cy.

Baseline characteristics of study population
The baseline characteristics of the seventy-eight patients received TBI/Cy and the forty-one patients received Bu/Cy regimens are described in Table 1. The age ranged from 19–49 to 19–41 years in the TBI/Cy and the Bu/Cy groups, respectively, with a mean age at transplant of 27.64 ± 7.67 in the TBI/Cy and 27.46 ± 7.00 in the Bu/Cy group. In the TBI/Cy group, 56 (71.8%) patients were males, and 22 (28.2%) were females, while in the Bu/Cy group, 73.2% of patients were males. B-ALL was the main subtype in both groups. Most of the patients in both groups had adequate performance. Philadelphia chromosome was positive in 18 (23.1%) patients in the TBI/Cy group and 9 (22%) patients in the Bu/Cy group.

At the time of transplant, 51.3% of patients were in CR1 in the TBI/Cy versus 39% in the Bu/Cy group. Among the 119 patients, only 14 patients were reported to have pre-transplant comorbidities which included diabetes, hypertension, and chronic liver disease. Female donors represented (42.3%) in the TBI group and (53.7%) in the Bu/Cy group. Female donors to male recipients were found in 24 patients in the TBI/Cy group and 16 patients in the Bu/Cy group. Seven patients (9%) in the TBI group had mismatched CMV donor versus 2 patients (4.9%) in the Bu group. The time from diagnosis to transplantation was ranged from 14 to 137.3 months in the TBI group and (4.9–73.2) months in the Bu/Cy group. All these differences were found to be statistically not significant.

Engraftment and GVHD
One hundred and eleven (93.3%) achieved engraftment and only eight patients (6.7%) had primary graft failure. Significant faster engraftment was observed in the Bu/Cy group, a median time to neutrophil engraftment was 17 days (range 9–35) in the TBI/Cy group and 14 days (range 10–24) in the Bu/Cy group, while the median time for platelet engraftment was 15 and 14 days in the TBI and the Bu groups, respectively (Table 2). However, no significant difference could be detected between the two groups in the term of engraftment by the multivariate analysis (Table 3). The incidence of acute and GVHD was similar in both groups (Table 2).

Fig. 1 Overall survival by Kaplan-Meier survival curve in ALL patients treated with either TBI/Cy (group 1) or Bu/Cy (group 2)
Relapse and NRM
Regarding relapse, 16.8% (n, 119) of patients developed relapse after transplant. A significantly high relapse rate was observed in the Bu/Cy group (26.8% versus 11.5% in the TBI/Cy group) (Table 2). The Bu/Cy regimen was identified as an independent risk factor for relapse by the multivariate analysis (Table 3). The incidence of NRM was similar in the two groups, which was proved by the univariate and multivariate analysis (Tables 2 and 3). The most common cause of NRM in the TBI group was sepsis (36.8%), while respiratory failure was the major cause in the Bu group (22.2%).

DFS and OS
The survival rate was 51.3% and 34.1% in the TBI/Cy and Bu/Cy group, respectively. The follow-up period ranged from (0.3–158) months in the TBI group with a median OS of 11 months, while it ranged from 0.3–118.5 months in the Bu group with a median OS of 6.2 months. The median DFS was 11.1 versus 6.8 months for TBI and Bu groups, respectively. The estimated 2-year OS was 42% in the TBI group and 44% in the Bu group. The estimated 2-year DFS was 80% in the TBI group compared to 55% in the Bu group. All these differences were statistically non-significant (Figs. 1 and 2).

No independent risk factors for low OS were detected by the multivariate analysis. Disease status at transplant was the only independent risk factor for poor DFS in both groups, and patients received a transplant at CR2 or beyond were associated with poor DFS, HR, 3.670 (CI 95% 1.500–8.978 and p 0.004). However, the disease status at transplant had no independent effect on relapse risk, OR, 0.420; CI 95% 0.149–1.182 (Tables 4 and 5).

Conditioning regimen related toxicity
Severe mucositis was significantly higher in the TBI/Cy group (37.2% versus 9.8% in the Bu/Cy group). A significantly higher incidence of bacterial infections was found in the TBI group (43.6 versus 24.5 % in the Bu/Cy group). Both groups had a similar incidence of VOD and hemorrhagic complications. Although eight patients (17.8%) had CMV reactivation after the transplant, this could not be proven when tested by multivariate analysis. In the TBI/Cy group, three patients developed idiopathic pneumonitis, and five patients developed osteoporosis as a complication of TBI regimen related toxicity (Table 6).
TBI-based regimens are widely used for ALL patients and are showing excellent outcomes without increasing the relapse rate. However, to avoid the wide range of long and short-term complications of TBI, the alternative radiation-free regimens based on Bu were introduced with the ability to produce comparable clinical results with lower transplant-related mortality and morbidity [3]. In the present study, we compared the clinical outcomes in two groups of ALL patients who underwent allo-HSCT using TBI/Cy conditioning versus a radiation-free regimen of oral Bu plus Cy.

Similar OS, DFS, and NRM were observed in both treatment groups; using multivariate analysis, the conditioning regimen was not an independent risk of OS, DFS, or NRM. However, patients who received a transplant in ≥CR2 had lower DFS in both groups. Relapse remains the leading reason for treatment failure, and a common cause of death in ALL patients received allo-HSCT. Using TBI is associated with lower relapse rates in many patients [11]. In this study, using the Bu/Cy regimen was accompanied by a significantly higher relapse rate that was confirmed in the multivariate analysis.

Recent research by Wang and colleagues who carried a retrospective analysis on 224 adult patients with ALL in Taiwan noted similar results; patients who received Bu/Cy or TBI conditioning had similar OS, DFS, and NRM. Disease status before HSCT was the only risk factor of survival in his patients with poor DFS in patients transplanted in ≥CR2 [12]. Another recent study published by the Center of International Blood and Marrow Transplantation (CIBMTR) concluded that the Bu/Cy patients had significantly more relapses than the TBI patients (HR, 1.46, 95% CI 1.15 to 1.85, \( p = .002 \)) [13], which was similar to our results. The advantage of TBI over busulfan in reducing post-transplant relapse was also confirmed in a large analysis by the European Society for Blood and Marrow Transplantation (EBMT) that reported a high rate of relapse in the Bu/Cy group of ALL patients transplanted in CR1 [14].

Unlike our findings, the authors of a recent meta-analysis including over 800 ALL patients reported lower DFS, better NRM with the oral Bu/Cy regimens than the TBI ones, and a similar risk of relapse [15]. In the Japanese retrospective analysis by Mitsuhashi and colleagues [16], in addition to a large meta-analysis of fifteen non-randomized comparative studies of 6280 patients [17], a lower NRM with TBI compared to oral Bu/Cy conditioning was reported without a significant difference in the relapse risk between both regimens, which was against our findings.

### Table 4
Multivariate analysis of overall survival and disease-free survival

| Endpoints of the study | HR (95% CI) | \( P \) |
|------------------------|-------------|--------|
| DFS                    |             |        |
| Variables              |             |        |
| Type of conditioning   | 1.391 (0.537–3.600) | 0.497 |
| Age of recipient       | 0.982 (0.898–1.073) | 0.685 |
| Sex of recipient       | 0.381 (0.115–1.263) | 0.115 |
| Disease status at BMT (CR1 vs ≥CR2) | 3.670 (1.500–8.978) | 0.004 |
| Ph chromosome status   | 1.303 (0.387–4.379) | 0.669 |
| Diagnosis to transplant lag | 0.961 (0.902–1.002) | 0.064 |
| OS                     |             |        |
| Variables              |             |        |
| Conditioning (TBI/Cy vs Bu/cy) | 0.764 (0.371–1.573) | 0.466 |
| Age of recipient (≤30 vs >30) | 1.014 (0.974–1.056) | 0.489 |
| Sex of recipient (Female vs male) | 1.461 (0.709–3.013) | 0.304 |
| Disease status at BMT (CR1 vs ≥CR2) | 1.660 (0.813–3.390) | 0.164 |
| Philadelphia chromosome status (Ph−ve vs Ph +ve) | 0.877 (0.400–1.922) | 0.743 |
| Diagnosis to transplant lag | 1.000 (0.985–1.014) | 0.946 |

HR hazard ratio, CI confidence interval

### Table 5
Analysis of risk factors of relapse among study participants

| Variables                      | Relapsed | Non relapsed | OR (95% CI) |
|--------------------------------|----------|--------------|-------------|
| Treatment group                |          |              |             |
| TBI/Cy                         | 9         | 69           | 0.356 (0.134–0.948) |
| Bu/Cy                          | 11        | 30           | 73.2        |
| Donor/recipient sex matching   |          |              |             |
| Mismatch                       | 15        | 58           | 2.121 (0.714–6.297) |
| Matching                       | 5         | 41           | 89.1        |
| Age in years                   |          |              |             |
| < 30                           | 12        | 61           | 0.934 (0.350–2.495) |
| ≥ 30                           | 8         | 38           | 82.6        |
| Phenotype                      |          |              |             |
| B                               | 11        | 68           | 86.1        |
| T                               | 9         | 31           | 77.5        |
| Philadelphia chromosome status  |          |              |             |
| Negative                       | 15        | 77           | 83.7        |
| Positive                       | 5         | 22           | 81.5        |
| Disease status at transplant    |          |              |             |
| CR 1                           | 6         | 50           | 89.3        |
| ≥ CR 2                         | 14        | 49           | 77.8        |
| Recipient sex                  |          |              |             |
| Females                        | 12        | 74           | 86.0        |
| Males                          | 8         | 25           | 75.8        |

OR Odds ratio, CI Confidence interval
A similar incidence of acute and chronic GVHD was observed among patients in both groups of the study, and this was similar to the findings published by Eroglu et al. [18].

For most MAC regimens including TBI, the incidence of severe mucositis ranged from 30 to 70%, increasing the risk of febrile neutropenia, serious infections, and the need for parenteral nutrition or narcotic therapy for pain control [19]. In this study, we demonstrated a significantly higher incidence of severe mucositis and bacterial infections associated with the use of TBI.

Previous studies reported an increased risk of VOD with the oral busulfan due to unpredictable absorption, supporting the use of the intravenous form to decrease the risk of such a fatal complication [5, 20]. Although fatal VOD was present in three patients in the Bu/Cy group compared to one patient in the TBI/Cy group, we could not find a significant impact of the conditioning regimen on the VOD risk in the multivariate analysis. Similarly, Sakellari et al. [21] found no significant difference in the VOD incidence among ALL patients who received TBI or Bu-based conditioning regimens. In contrast, we disagreed with the findings of a retrospective study by Kalaycio et al. who noted a higher incidence of VOD in patients received oral busulfan compared to those in the TBI group [22].

It should be noted that our study did not provide data on the plasma level of oral busulfan due to it was unavailable in a standardized lab in our country during the study period; it is unknown to what degree the dose adjustment according to the oral busulfan plasma level may have contributed to our findings.

Among our study participants, sepsis was the main cause of death in the TBI/Cy group, followed by relapse and organ failure. While in the Bu/Cy group, relapse was the leading cause of mortality followed by respiratory failure and sepsis. These findings were similar to a recent report from the CIBMTR [23].

**Conclusion**

The two regimens offer sufficient immunosuppression facilitating engraftment, without significant difference in OS or DFS. The Bu/Cy regimen was associated with a higher risk of relapse compared to the TBI-based one. In this study, the TBI-based regimen appears to be slightly superior to the Bu/Cy one in terms of low relapse rates. The variability in the absorption and metabolism of the oral busulfan formulation could be the cause of plasma-level differences that can cause many conflicting results and toxicity with the two regimens.

**Study limitations**

We must address the limitations of this study. This is a retrospective study with a relatively small number of participants. It is also worth mentioning that the intravenous Bu could not be used due to unavailability in our country. Despite these limitations, we had a relatively homogenous group of patients with similar baseline characteristics who received transplants in a large transplantation center using the standard procedures and had the advantage of a long period of follow-up in most of the patients. Our data might provide the basis for further larger prospective studies aiming at optimizing the conditioning regimens in adult ALL.

**Abbreviations**

Allo-HSCT: Allogeneic hematopoietic stem cell transplantation; ALL: Acute lymphoblastic leukemia; CIBMTR: Center of international blood and marrow transplantation registry; DFS: Disease-free survival; EBMT: The European Society for Blood and Marrow Transplantation; GVHD: Graft versus host disease; G-CSF: Granulocyte colony-stimulating growth factors;
MAC: Myeloablative conditioning; NRM: Non-relapse mortality; OS: Overall survival; VOD: Veno-occlusive disease

Acknowledgements
Not applicable

Authors’ contributions
MMA and GMF contributed to the concept and data collection. IK analyzed and interpreted the patient data and had a major role in the revision of the manuscript. MMA wrote the manuscript. MMA, IK, AG, and AT shared in the revision of the article. All authors have read and approved the manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The baseline data that support the finding of this work were obtained from BMT unit registry of Nasser institute after permission.

Ethics approval and consent to participate
The study was conducted by the stipulations of the local ethical and scientific committee of Tanta University, Egypt. Ethics approval code number 31611. The files were retrieved after concealing the personal details of patients to keep the confidentiality of data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Internal Medicine Department, Hematology/Bone marrow transplantation unit, Tanta University, Tanta, Algharbia, Egypt. 2Nasser Institute Hospital for Research and Treatment, Cairo, Egypt. 3Public Health and Community Medicine Department, Tanta University, Tanta, Egypt.

Received: 24 March 2020 Accepted: 19 May 2020
Published online: 15 June 2020

References
1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52.
2. Thomas X, Le Jeune C. Current management of adult acute lymphoblastic Leukemia: Emerging insights and outstanding questions. BMJ Hematol. 2016;4(1):117–28.
3. Tracey J, Zhang MJ, Thiel E, Sobocinski KA, Eapen M. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2013 Feb 1;19(2):255–9.
4. Mori T, Asia Y, Kato J, Yamane A, Nakazato T, Shigematsu N, et al. Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Ann J Hematol. 2012 Apr;87(4):349–53.
5. Palmer J, McCune JS, Peralez MA, Marks D, Bubalo J, Mothy M, et al. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22(1):1915–25.
6. Ratajczak MZ, Suszynska M. Emerging strategies to enhance homing and engraftment of hematopoietic stem cells. Stem Cell Rev Rep. 2016;12(1):121–8.
7. Goyal RK, Voller D, Goyal M, Sankaranarayanan K. Grading acute GVHD, getting it right every time! Biol Blood Marrow Transplant. 2015;21(2):518.
8. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30–7.
9. Mothy M, Malar F, Abecassis M, Aerts E, Alskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–12.
10. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009 May 28;4(03).
11. Chen R, Campbell JL, Chen B. Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. OncoTargets Therapy. 2015;8:405–12.
12. Wang YH, Ko BS, Liao XY, Yao M, Tang JL. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem-cell transplantation for acute lymphoblastic leukemia: single tertiary center experience in Taiwan. Biol Blood Marrow Transplant. 2019;25(3):5188.
13. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(1):76–33.
14. Giebel S, Labopin M, Socie G, Beelen D, Browne P, Yolli L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(1):139–49.
15. Shi-Xia X, Xian-Hua T, Hai-Qin X, Bo F, Xiang-Feng T. Total body irradiation plus cyclophosphamide versus busulfan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma. 2010;51(1):50–60.
16. Mitsushashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017;23(2):1949–200.
17. Gupta T, Kannan S, Dantkale V, Laskar S. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011;4(1):17–29.
18. Erolgu C, Pala C, Kayrur L, YayKay K, Aksozen MT, Bankir M, et al. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2013;54(11):2474–9.
19. Vasquezn K, Ruble K, Chen A, Biflet C, Kozlowski L, Atwater S, Kost-Byerly S. Pain management for children during bone marrow and stem cell transplantation. Pain Manag Nurs. 2015;16(3):516–62.
20. Sobocinski KA, Thall PF, Bekele BN, Klein JP, Lennson S, Horowitz MM, et al. Matched pairs analysis of IV vs PO busulfan as a conditioning agent prior to transplantation. ASH Annual Meeting abstract. Blood. 2004;104(1):349.
21. Sakellari I, Gavriilaki E, Chatziioannou K, Papathanasiou M, Mallouri D, Batsis I, et al. The results of allogeneic hematopoietic cell transplantation: a meta-analysis. Leuk Lymphoma. 2016;51(7):906–12.
22. Kalaycio M, Bolwell B, Rybicki L, Absi A, Andresen S, Pohlman B, et al. BU-vs CYC regimen for allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2011;17(6):943–6.
23. D’Souza A, Fretlarm C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CBMT summary slides. Center for International Blood & Marrow Transplant Research. https://www.cibmtr.Org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx Updated June. 2018 Jun; 13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.